CVS/Caremark Corporation: Q1 2007 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the thirteen-week period ended March 31, 2007. The reporting period is defined by the completion of the merger with Caremark Rx, Inc. on March 22, 2007. Following the merger, the company changed its name to CVS/Caremark Corporation. The consolidated results include approximately 10 days of Caremark operations. The company operates two primary segments: Retail Pharmacy and Pharmacy Benefit Management (PBM).
Key Financial Metrics
| Metric (in millions) | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Revenues | $13,184.6 | $9,979.2 |
| Gross Profit | $3,349.2 | $2,649.0 |
| Operating Profit | $736.5 | $560.5 |
| Net Earnings | $408.9 | $329.6 |
| Diluted EPS | $0.43 | $0.39 |
| Operating Cash Flow | $707.7 | $171.7 |
| Cash and Equivalents (End of Period) | $710.7 | $387.1 |
| Total Debt (Short-term + Long-term) | $6,810.8 | N/A (Pre-merger) |
Note: Total debt includes $3,072.8M short-term debt, $842.6M current portion of long-term debt, and $2,895.4M long-term debt as of March 31, 2007.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 32.1% to $13.2 billion. The Retail Segment grew 23.1%, while the PBM Segment surged 136.8% due to the inclusion of Caremark operations.
- Profitability: Net earnings rose 24.1% to $408.9 million. Operating profit increased 31.4% to $736.5 million.
- Balance Sheet Expansion: Total assets more than doubled from $20.6 billion to $51.0 billion, primarily driven by the acquisition of Caremark. Goodwill increased from $3.2 billion to $28.5 billion.
- Debt Levels: Significant increases in short-term debt ($3.1 billion) and long-term debt were incurred to fund the Caremark merger special dividend and a concurrent share tender offer.
- Same-Store Sales: Retail same-store revenues increased 7.5%, with pharmacy sales up 7.8% and front-store sales up 6.6%.
Outlook, Risks, and Management Commentary
- Merger Integration: Management expects significant benefits from purchasing scale and operating synergies, including reduced overhead and prescription dispensing costs. However, $25.3 million in integration costs were incurred in Q1.
- Capital Structure: The company launched a tender offer for 150 million shares at $35.00 per share, resulting in 10.3 million shares tendered. A 23% dividend increase to $0.06 per share was declared.
- Guidance: The company anticipates its effective annual income tax rate will increase to 39.7% for fiscal 2007 due to the merger. Plans include opening 175-200 new or relocated retail stores for the remainder of 2007.
- Risks and Contingencies:
- Legal Proceedings: Multiple lawsuits remain pending, including a Delaware Chancery Court settlement regarding the merger (attorneys' fees up to $20 million), antitrust litigation regarding PBM networks, and a qui tam lawsuit regarding Medicaid claims.
- Regulatory Environment: Risks include changes in Medicaid reimbursement rates (Deficit Reduction Act of 2005) and Medicare Part D utilization impacts.
- Market Risks: Exposure to generic drug conversion, mail-order channel growth, and third-party payer cost-reduction efforts.
Investor Verification Checklist
- Verify the final allocation of the $26.9 billion purchase price for the Caremark merger, as current figures are preliminary.
- Monitor the outcome of the Delaware Chancery Court settlement hearing scheduled for June 8, 2007, regarding merger-related litigation.
- Track the company's ability to refinance short-term borrowings (commercial paper and bridge loans) into long-term debt in Q2 2007.
- Assess the impact of the 39.7% projected effective tax rate on future earnings per share.
- Review the status of the pending antitrust litigation (In Re Pharmacy Benefit Managers Antitrust Litigation) and its potential financial impact.